- Tens of millions of Americans live in areas where mental health providers are scarce
- Delic is working on making psychedelic-based treatments more accessible and affordable
- In 2021, the company acquired Ketamine Infusion Centers (“KIC”) and Ketamine Wellness Centers, becoming the owner and operator of the largest chain of wellness clinics administering ketamine treatments in the U.S.
A May 2021 CNBC article exploring the cost and accessibility of mental health care in the United States noted that the number of Americans experiencing depression and anxiety had increased – a total of 42% of U.S. adults had reported symptoms, up from 11% in preceding years – due to the COVID-19 pandemic, among other factors (https://ibn.fm/1HcId).
“Spending on mental health treatment and services reached $225 billion… That number, which is up 52% since 2009, includes spending on things like therapy and prescription medication as well as stays in psychiatric or substance abuse rehabilitation facilities. It doesn’t take into account indirect costs, such as lower workforce participation rates and decreased productivity… And access to care can be prohibitively expensive,” the article notes.
While overall access and coverage for mental health and substance abuse treatments have improved over the years, the article discusses a number of other factors that still make it difficult for patients to get affordable care.
“Mental health and substance use treatment centers and clinics, for instance, tend to be concentrated in urban areas. Rural parts of the country tend to lack access to more specialized treatment options… In fact, more than 112 million Americans live in areas where mental health providers are scarce,” the article adds.
For Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, the prohibitive costs and limited access to mental health care are primary motivators. Accordingly, the company is working to make psychedelic-based treatments more accessible and affordable by leveraging its growing psychedelic wellness clinics in the United States.
In 2021, Delic completed the acquisitions of Ketamine Infusion Centers (“KIC”), a limited liability corporation that owns and operates a ketamine infusion treatment clinic in Phoenix, Arizona, and Ketamine Wellness Centers (“KWC”), the largest national chain of wellness clinics in the United States (https://ibn.fm/iNRwR).
These acquisitions brought the number of operational wellness clinics under the Delic umbrella to 12, cementing the company’s position as the owner and operator of the largest, most profitable chain of mental health clinics in the United States.
According to Delic, these clinics are strategically located in secondary cities to improve accessibility and reach as well as help the greatest number of patients. Still, the company plans to serve even more people with the opening of 14 additional clinics over the next 18 months as well as expansion into localities where access to mental health treatments is limited (https://ibn.fm/3owEb).
The U.S., Delic Co-founder and CEO Matt Stang notes, is home to 51.5 million people who have experienced a mental health condition, and the pandemic has only exacerbated the crisis. Furthermore, the company is seeing strong demand for alternatives to current treatments with lasting outcomes and fewer side effects and has, in fact, released the findings of a commissioned study investigating this very fact.
The study, conducted on its behalf by The Harris Poll, shows that a large number of Americans who suffer from anxiety/depression/PTSD believe that psychedelic medicine such as ketamine, psilocybin, and MDMA should be availed to patients with treatment-resistant anxiety, depression, or PTSD. In addition, significant percentages of those polled would be open to pursuing treatment using psychedelic medicine if they were individually proven more effective than prescription drugs with fewer side effects (https://ibn.fm/pXXls).
“At Delic, we have built the most profitable model for scaling the best-in-class care directly to patients through the largest network of mental health clinics in the U.S. We see a strong outlook for Delic with the rollout of 14 additional clinics and an expansion into communities where access to these life-changing treatments is very limited. Delic is well-positioned for growth and profitability in 2022 and beyond,” concluded Stang.
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
